AI assistant
AGRONOMICS LIMITED — Net Asset Value 2013
Jan 25, 2013
7474_rns_2013-01-25_26a685cd-cc41-4452-a119-526071f923f7.html
Net Asset Value
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 4243W
Port Erin Biopharma Investments Ltd
25 January 2013
Port Erin Biopharma Investments Limited ("the Company")
Net Asset Value calculation to 31st December 2012
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2012 was 9.50 pence per share, including un-invested cash of £101,241. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a small decrease from the previous valuation of 9.63 pence per share, which included un-invested cash of £329,708. The revenue reserve has increased substantially following the deduction of listing expenses from the share premium account and still represents a return of over 16.0% on investments after operating costs. Indeed, if the NAV valuation were to be published today, the NAV per share would approach 10.4 pence."
| Unaudited 15 September 2011 to 31 December 2012 £ |
||
| Fixed Assets | ||
| Investments | 3,031,135 | |
| Current Assets | ||
| Debtors: amounts owing | 9,035 | |
| Un-invested cash | 101,241 | |
| Current Liabilities | ||
| Creditors: amounts due | (7,292) | |
| 3,134,119 | ||
| Capital and Reserves | ||
| Share Capital | 33 | |
| Share Premium | 2,699,011 | |
| Capital reserve - realised | 0 | |
| Capital reserve - unrealised | 0 | |
| Revenue reserve | 435,075 | |
| 3,134,119 | ||
| Shares in Issue | 33,000,000 | |
| Net Asset Value per share | 9.50 pence |
--- ENDS ---
Portfolio Details
| Investments Schedule at 31st December 2012 | Valuation £ | Portfolio % |
| Summit Corporation plc | £269,166.87 | 8.88% |
| Cytox Limited | £200,000.00 | 6.60% |
| Gilead Sciences Inc. | £195,452.13 | 6.45% |
| Synergy Pharmaceuticals Inc. | £182,814.82 | 6.03% |
| Plethora Solutions Holdings plc | £180,000.00 | 5.94% |
| Celgene Inc. | £141,125.68 | 4.66% |
| Astellas Pharma Inc. | £140,762.00 | 4.64% |
| Arrowhead Resources | £135,419.97 | 4.47% |
| TrovaGene Inc. | £127,845.13 | 4.22% |
| Abbott Laboratories | £117,762.25 | 3.89% |
| Pfizer Inc. | £114,835.48 | 3.79% |
| £1,805,184.33 | 59.55% | |
| Aggregate value of remaining holdings below 3% of total portfolio | £1,225,950.25 | 40.45% |
| TOTAL INVESTMENTS | £3,031,134.58 | 100.00% |
For further information, please contact:
| Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
| The Company | Nomad | Broker |
| Denham Eke +44 162 463 9396 |
Sandy Jamieson +44 207 569 9650 |
Jon Levinson +44 207 562 3350 |
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVLLFFELRIEFIV